Form 483 outcomes

What happens after an FDA Form 483

Most Form 483s do not lead to a warning letter. In FDA's inspection data from fiscal 2013 to late 2025, about 6% of inspections with posted 483 citations were followed by a warning letter to the same site within a year, about 1 in 17. The classification decides most of it: about half of OAI inspections were followed by a letter within a year, against under 1% of VAI inspections. And findings come back: at more than half of re-inspected sites, FDA cited something it had cited at the site's previous inspection.

No key needed for the check. For the full record, connect RegDataLab or use the API.

What the data shows

About 1 in 17 get a warning letter

Of 53,221 inspections with posted Form 483 citations, 6.0% were followed by a warning letter to the same site (FEI) within 365 days, and 4.2% within 180 days.

OAI is the real signal

52% of OAI inspections were followed by a warning letter within a year. VAI: 0.5%. NAI: 3.3%, where the letter rests on something other than that inspection.

More than half repeat a finding

Of 18,093 re-inspections with an earlier Form 483 at the same site within five years, 57% cited at least one of the same observations again. 28% of all observations on those visits were repeats.

Repeats double the odds

Re-inspections with a repeat observation were followed by a warning letter within a year 8.8% of the time, against 4.1% when nothing repeated.

Warning letter within a year of a Form 483, by product area

Inspections with posted Form 483 citations, fiscal 2013 to November 2025, by FDA product type
Product typeInspectionsWarning letter within 365 days
Veterinary3,57311.3%
Drugs7,0218.6%
Devices9,2765.8%
Food and cosmetics30,6685.2%
Biologics2,6832.7%
All53,2216.0%

The findings that come back most

Across all product areas, the observations most often cited again at the next inspection were developing a foreign supplier verification program (FSVP), sanitation monitoring, written procedures, HACCP plan implementation, complaint procedures and pest exclusion.

For drug and device sites, the repeats that come up most are specifications for identity, purity, strength and composition, purchasing controls, written manufacturing procedures, and investigations of discrepancies and failures. Repeats are more likely the sooner FDA returns: 65% of re-inspections within two years repeated a finding, against 49% after three to five years.

How we counted

We used the inspection citations FDA publishes on its Data Dashboard as the record of a Form 483, and the Dashboard classification (NAI, VAI or OAI) of each inspection. A warning letter counts when FDA issued it to the same site, matched by FEI number, after the inspection ended. The cohort runs from October 2012 to one year before the newest letter, so every inspection had a full year. Warning letters to tobacco retailers are left out.

A repeat means the same FDA standard observation wording at the site's previous inspection with a Form 483, within five years. It is not FDA's own repeat note, which appears in the 483 text.

These are base rates across all sites. A letter that follows a Form 483 is not proof that the 483 caused it, and the rates do not predict what happens to any one company. Form 483s that FDA did not record in its electronic tools are not in the data.

Ask it in Claude or ChatGPT

  • Did any of my suppliers have a Form 483 in the last two years that repeated a finding from their previous inspection?
  • Show [company]'s inspections with their classification, Form 483 citations and any warning letter that followed.
  • Which drug sites had an OAI inspection this year and no warning letter yet?
  • List the CFR sections cited at [site] in each of its last three inspections, side by side.

50 credits now, 300 credits a month once you verify your email.

Connect Claude or ChatGPT from the FDA MCP server page. Plan limits are on pricing.

Questions

What happens after an FDA Form 483?
The company usually answers in writing within 15 business days. FDA then classifies the inspection: NAI (no action indicated), VAI (voluntary action indicated, problems found but no regulatory action recommended) or OAI (official action indicated, regulatory or administrative action recommended). OAI can lead to a warning letter, an import alert or other action. In FDA's data from fiscal 2013 to late 2025, about 6% of inspections with Form 483 citations were followed by a warning letter to the same site within a year.
What are the chances a Form 483 becomes a warning letter?
About 6% within a year overall, and about 4% within six months. The classification matters most: about half of OAI inspections were followed by a warning letter within a year, against under 1% of VAI inspections.
How long after a Form 483 does a warning letter come?
Often within months. About two thirds of the letters that followed within a year came within six months of the inspection ending. Some come later, and some rest on a different inspection, a records request or an import sample.
What is a repeat observation, and how common is it?
A repeat observation is a finding FDA already cited at the site's previous inspection. In FDA's citation data, more than half of re-inspected sites with an earlier Form 483 within five years were cited for at least one of the same observations again, and those re-inspections were followed by a warning letter about twice as often.
How do I check a supplier's Form 483 history?
Type the company name in the check on this page. It returns the company's inspections, Form 483 citations and warning letters, tied to each site. In Claude or ChatGPT, ask RegDataLab for a supplier's inspections and whether any finding repeated. No matching records does not mean a company is safe.
How do I use RegDataLab in Claude or ChatGPT?
Add https://www.regdatalab.com/mcp as a custom connector (Claude: Customize, Connectors, Add custom connector; ChatGPT: Plugins, Add, Add custom MCP server, Authentication OAuth), sign in with your email on the RegDataLab page (no API key needed), then ask in plain English. 50 credits now, 300 credits a month once you verify your email.
Is RegDataLab part of the FDA?
No. RegDataLab is an independent data product built on public FDA records. It is not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration.